Thomas Colacchio
Cancer and Leukemia Group B
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Thomas Colacchio as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:39 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT00002968 · Edrecolomab in Treating Patients With Stage II Colon CancerNational Cancer Institute (NCI) · completed · Mucinous Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Colon, Stage IIA Colon Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT00002968
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:39 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group.N Engl J Med · 1994600 citationsRCR 19.4
- 136 citationsRCR 3.0
- 55 citationsRCR 1.2
- Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).J Clin Oncol · 200847 citationsRCR 1.2